华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06132 华健未来-B

未开盘 09-30 16:08:26

36.080

-0.120

-0.33%

最高38.220	最低36.080	成交量5.17万
今开36.100	昨收36.200	日振幅5.91%
总市值26.55亿	流通市值26.55亿	总股本7,360万
成交额188.74万	换手率0.07%	流通股本7,360万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06132","market":"HK","secType":"STK","nameCN":"华健未来-B","latestPrice":36.08,"timestamp":1790755706170,"preClose":36.2,"halted":0,"volume":51700,"delay":0,"changeRate":-0.0033149171270719486,"floatShares":73599600,"shares":73599605,"eps":-2.28,"marketStatus":"未开盘","change":-0.12,"latestTime":"09-30 16:08:26","open":36.1,"high":38.22,"low":36.08,"amount":1887432,"amplitude":0.059116,"askPrice":36.16,"askSize":100,"bidPrice":36.08,"bidSize":1100,"shortable":0,"etf":0,"ttmEps":-2.434,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":0,"adr":0,"listingDate":1782144000000,"exchange":"SEHK","adjPreClose":36.2,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":0.7826218596269652,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06132/wiki","defaultTab":"wiki","newsList":[{"id":"1145579350","title":"华健未来-B2026年9月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1145579350","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145579350?lang=zh_cn&edition=full","pubTime":"2026-09-30 19:22","pubTimestamp":1790767366,"startTime":"0","endTime":"0","summary":"华健未来（成都）生物科技股份有限公司于2026年9月30日披露了2026年9月股份变动月报表，报告期为截至2026年9月30日。公告显示，公司法定/注册股本数为人民币73,599,605元，已发行普通股H股股数为73,599,605股，面值为每股人民币1元。与上个月相比，本期股本保持不变。此外，公司确认，截至9月30日已符合香港联交所关于最低公众持股量的要求。公司同时重申已遵守香港联交所《上市规则》及相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146965295","title":"华健未来-B（06132）公布最新董事会及三大专门委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1146965295","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146965295?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:16","pubTimestamp":1789381000,"startTime":"0","endTime":"0","summary":"2026年9月14日，华健未来（成都）科技股份有限公司在港交所披露董事名册及其在各专门委员会中的职能分工。公司现设审核委员会、薪酬与考核委员会及提名委员会。上述董事会及各专门委员会的组成信息以2026年9月14日发布的公告为准。公司称，相关董事及委员会成员的任命已按香港联合交易所有限公司及公司章程的有关规定履行必要程序。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152839861","title":"华健未来-B（06132）公布2026年9月14日临时股东大会表决结果 全部议案获高票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1152839861","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152839861?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:13","pubTimestamp":1789380790,"startTime":"0","endTime":"0","summary":"2026年9月14日，华健未来-B在成都召开临时股东大会。会议就五项特别决议案及两项普通决议案进行投票表决，所有议案均获股东正式通过。以下为核心数据：。会议当日公司已发行H股总数为73,599,605股。出席会议并行使表决权的股东及其受委代表合计持有52,488,060股，占已发行股份总数约71.32%。变更公司名称：赞成票52,488,060股，反对及弃权票均为0股。两项普通决议案均获过半数投票赞成，顺利通过。香港中央证券登记有限公司作为本次临时股东会的点票监票人。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141345318","title":"华健未来-B8月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1141345318","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141345318?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:01","pubTimestamp":1788426101,"startTime":"0","endTime":"0","summary":"华健未来（成都）科技股份有限公司于2026年9月3日发布截至2026年8月31日的股份变动月报表。根据公告显示，截至8月底，公司无新增股份发行、回购、注销或库藏股变动，股本规模保持稳定。截至报告期末，公司确认符合香港联交所规定的最低公众持股量要求。公告同时显示，本月并无股份期权、权证或可换股票据等方面的发行或变动。公司表示将继续密切关注股本情况，确保合规稳健运营。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663609096","title":"华健未来-B(06132)发布中期业绩，股东应占亏损7347.5万元 同比增加38.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663609096","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663609096?lang=zh_cn&edition=full","pubTime":"2026-08-29 01:09","pubTimestamp":1787936977,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华健未来-B(06132)发布截至2026年6月30日止6个月的中期业绩，该集团取得收入人民币194.3万元(单位下同)，同比增加118.1%;本公司拥有人应占亏损7347.5万元，同比增加38.77%;每股亏损1.21元。公告称，收入增加主要由于2025年7月收到筠泽创曜的2000万元里程碑付款以及集团于报告期内持续履行相关研发服务履约义务，按成本投入法计量的履约进度提高。该款项乃根据实际产生成本占全面履行集团履约义务所需估计总成本的百分比随时间确认为收入，而未确认部分则呈列为合约负债。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100384524","title":"华健未来-B 2026年中期业绩：收入194.30万元，经调整净亏损4,730.20万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100384524","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100384524?lang=zh_cn&edition=full","pubTime":"2026-08-28 23:04","pubTimestamp":1787929440,"startTime":"0","endTime":"0","summary":"2026年上半年，华健未来-B（股票代码：06132）实现收入194.30万元，同比增长118.1%。同期，公司经调整净亏损为4,730.20万元，同比收窄10.7%。\n报告期内，华健未来-B的研发开支为4,625.50万元，较上一年同期增长13.1%。同时，行政开支约2,096.40万元，相比上一期约911.90万元增长约130%。经营活动所用现金净额约5,377.60万元，与上年同期基本持平。\n截至2026年6月30日，公司持有的现金及现金等价物为11.07亿元，同比增长29,654.9%。\n(文中金额如无特别说明，均已根据公告“人民币千元”口径换算后四舍五入，单位为“万元”或“亿元”)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"华健未来-B 2026年中期业绩：收入194.30万元，经调整净亏损4,730.20万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180701810","title":"华健未来-B（06132）拟于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1180701810","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180701810?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:41","pubTimestamp":1787042488,"startTime":"0","endTime":"0","summary":"2026年8月18日，华健未来（成都）科技股份有限公司发布公告称，公司董事会会议定于2026年8月28日（星期五）举行，届时将审议并批准本公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜。公告显示，会议由执行董事、董事长、首席执行官兼总经理姬建新博士签署。公司表示，有关中期业绩的详细内容以及董事会决议结果将于适当时间另行公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484037","title":"华健未来-B(06132.HK)建议委任王力源及方圣石为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484037","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660484037?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:22","pubTimestamp":1786965749,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484785","title":"华健未来-B(06132.HK)拟更名为“华健未来(成都)生物科技股份有限公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484785","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660484785?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:19","pubTimestamp":1786965540,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06132","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660842574","title":"华健未来-B(06132)建议采纳2026年H股激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2660842574","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660842574?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:16","pubTimestamp":1786965413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华健未来-B(06132)发布公告，公司董事会已决议，待先决条件达成后，采纳H股激励计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06132","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115094329","title":"华健未来-B（06132）拟于2026年9月14日召开临时股东会 审议更名、H股激励计划及回购授权等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1115094329","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115094329?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:15","pubTimestamp":1786965339,"startTime":"0","endTime":"0","summary":"华健未来-B8月17日公告称，公司将于2026年9月14日上午十时在中国成都市温江区八一路北段18号三医创新中心D8栋一楼会议室召开临时股东大会，就五项特别决议案及两项普通决议案进行表决。参加大会的H股股东名册将于2026年9月9日至2026年9月14日期间暂停办理股份过户登记；欲出席会议的未登记股东需在2026年9月8日16时30分前完成过户手续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145028498","title":"华健未来-B（06132）发布多项议案：拟实施2026年H股激励计划并更名","url":"https://stock-news.laohu8.com/highlight/detail?id=1145028498","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145028498?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:15","pubTimestamp":1786965336,"startTime":"0","endTime":"0","summary":"8月17日，华健未来（成都）科技股份有限公司公告称，董事会已通过四项关键议案，拟于即将召开的临时股东大会上提交表决。– 该计划构成香港联交所《上市规则》第17章项下的股份奖励计划。公司将另行寄发通函披露计划完整条款。– 拟变更为“华健未来（成都）生物科技股份有限公司”，英文名称保持不变；公司表示，相关通函及临时股东大会通知将适时寄发股东，以供审议上述全部议案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172141228","title":"华健未来-B 7月股份变动月报表：股本维持73,599,605股","url":"https://stock-news.laohu8.com/highlight/detail?id=1172141228","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172141228?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:57","pubTimestamp":1785833831,"startTime":"0","endTime":"0","summary":"华健未来（成都）科技股份有限公司于2026年8月4日披露2026年7月股份变动月报表，报告期为2026年7月1日至7月31日。公告显示，公司注册地为中华人民共和国，法定注册股本为人民币73,599,605元，面值每股人民币1元。根据月报披露，报告期初普通H股发行总数为73,599,605股，期间无新增发行、回购、注销及库藏股变动，期末已发行股份总数维持在73,599,605股。公司在公告中进一步声明，其所有股权变动事项均符合相关上市规则及法律法规的规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652404904","title":"华健未来-B(06132)：稳定价格行动、稳定价格期结束及超额配股权失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2652404904","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652404904?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:00","pubTimestamp":1784282428,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华健未来-B 发布公告，根据香港法例第571W章证券及期货规则第9条，公司宣布，有关全球发售的稳定价格期于2026年7月17日(星期五)结束。公司进一步宣布，独家整体协调人于稳定价格期内并无行使超额配股权，而超额配股权于2026年7月17日(星期五)失效。因此，本公司概无根据超额配股权已发行或将予发行任何H股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153407143","title":"华健未来-B6月股份维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1153407143","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153407143?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:26","pubTimestamp":1783330011,"startTime":"0","endTime":"0","summary":"华健未来（成都）科技股份有限公司于2026年7月6日发布截至2026年6月30日的证券变动月报表。公告显示，公司本月股本保持稳定，无新增发行、购回或注销股份及其他库藏股变动。根据公告，公司期末普通股H股的已发行股份总数和注册股本与上月末一致，均为73,599,605股，总面值为人民币73,599,605元。据公告披露，本次月报表由联席公司秘书张菁洁签署。公司表示将持续加强规范运作，维护方面确保股东合法权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119941497","title":"异动解读｜华健未来-B盘中下跌9.37%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119941497","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119941497?lang=zh_cn&edition=full","pubTime":"2026-07-03 10:16","pubTimestamp":1783045016,"startTime":"0","endTime":"0","summary":"7月3日，华健未来-B盘中下跌9.37%，报37.6港元/股，成交额70.27万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，各赛道竞争激烈。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129586220","title":"异动解读｜华健未来-B盘中上涨8.75%，报39.02港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129586220","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129586220?lang=zh_cn&edition=full","pubTime":"2026-07-02 13:31","pubTimestamp":1782970315,"startTime":"0","endTime":"0","summary":"7月2日，华健未来-B盘中上涨8.75%，报39.02港元/股，成交额539.2万港元。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。公司于6月23日以81.8港元/股发行价登陆港交所，作为18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145308583","title":"异动解读｜华健未来-B盘中下跌8.07%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145308583","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145308583?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:47","pubTimestamp":1782784048,"startTime":"0","endTime":"0","summary":"6月30日，华健未来-B盘中下跌8.07%，报37.3港元/股，成交额175.19万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，各赛道竞争激烈。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187245908","title":"异动解读｜华健未来-B盘中下跌8.12%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187245908","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187245908?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:46","pubTimestamp":1782701172,"startTime":"0","endTime":"0","summary":"6月29日，华健未来-B盘中下跌8.12%，报40.5港元/股，成交额444.59万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，且各赛道竞争激烈。叠加近期恒指持续走弱，市场资金偏好转向AI等高成长板块，未盈利生物科技标的遭遇系统性抛压，股价延续调整态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154895339","title":"异动解读｜华健未来-B盘中上涨8.96%，报38.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154895339","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154895339?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:11","pubTimestamp":1782353475,"startTime":"0","endTime":"0","summary":"6月25日，华健未来-B盘中上涨8.96%，报38.9港元/股，成交额674.63万港元。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。公司于6月23日以81.8港元/股发行价登陆港交所，上市首日收报35.26港元，跌幅达56.89%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hj3h.com","stockEarnings":[{"period":"1week","weight":-0.1247},{"period":"1month","weight":-0.2244},{"period":"3month","weight":-0.1285},{"period":"6month","weight":-0.5589},{"period":"ytd","weight":-0.5589}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.0676},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华健未来（成都）科技股份有限公司是一家主要从事小分子新药研发的中国公司。该公司主要产品包括选择性酪氨酸激酶2（TYK2）抑制剂HJ787、可口服药物HJ178、口服Kirsten大鼠肉瘤2病毒癌基因同源物（KRAS）G12C抑制剂HJ891、以及候选药物HJ197、HJ356、HJ093及HJ199。该公司产品主要用于治疗自身免疫范畴的各种皮肤病、2型糖尿病、超重或肥胖、心血管疾病及动脉粥样硬化、非小细胞肺癌（NSCLC）、晚期肝细胞癌（HCC）等疾病。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"华健未来-B","nameEN":"HJ SCIENCE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华健未来-B(06132)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华健未来-B,06132,华健未来-B股票,华健未来-B股票老虎,华健未来-B股票老虎国际,华健未来-B行情,华健未来-B股票行情,华健未来-B股价,华健未来-B股市,华健未来-B股票价格,华健未来-B股票交易,华健未来-B股票购买,华健未来-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华健未来-B(06132)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}